Jasper Therapeutics will present preliminary data from the BEACON study of briquilimab, which could enhance the visibility and interest in their novel antibody therapy. The inclusion of Dr. Thomas B.
Rezolute, Inc. Announces Late-Breaking Presentation of Phase 3 Study Data for Ersodetug at ENDO 2025
Rezolute, Inc., a company focused on treating hypoglycemia caused by hyperinsulinism, announced that its abstract for a Phase 3 study of its drug Ersodetug will be presented at ENDO 2025 in San ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results